Table F3Accuracy of Doses Administered to Heterozygous F1 p53+/− Mice in the 30-Week, 45-Week, and 45-Week Stop-Exposure In Utero/Postnatal Gavage Studies of AZT

Date AnalyzedTarget Dose (mg)Actual Dose (mg)aDifference From Target (%)
November 29, 20044.874.44 ± 0.09-9
9.678.92 ± 0.33-8
December 06, 20040.480.47 ± 0.01-2
3.2483.05 ± 0.10-6
December 09, 20041.441.43 ± 0.03-1
7.206.89 ± 0.25-4
January 11, 20051.441.36 ± 0.02-5
7.206.69 ± 0.10-7
March 03, 20051.441.40 ± 0.05-3
7.206.75 ± 0.09-6
March 16, 20051.441.44 ± 0.040
7.206.98 ± 0.23-3
April 29, 20051.441.37 ± 0.02-5
7.206.62 ± 0.07-8
July 07, 20051.441.34 ± 0.04-7
7.206.43 ± 0.24-11
September 14, 20057.206.20 ± 0.16-14
September 21, 20057.206.80 ± 0.08-5
December 09, 20057.206.44 ± 0.07-10
January 25, 20067.207.02 ± 0.12-2
a

Results of triplicate analyses (mean ± standard deviation).

From: APPENDIX F, CHEMICAL CHARACTERIZATION AND DOSE FORMULATION STUDIES

Cover of NTP Genetically Modified Model Report on the Toxicology and Carcinogenicity Studies of 3’-Azido-3’-Deoxythymidine (CASRN 30516-87-1) in Genetically Modified C3B6.129F1-Trp53tm1Brd N12 Haploinsufficient Mice (In Utero and Postnatal Gavage Study)
NTP Genetically Modified Model Report on the Toxicology and Carcinogenicity Studies of 3’-Azido-3’-Deoxythymidine (CASRN 30516-87-1) in Genetically Modified C3B6.129F1-Trp53tm1Brd N12 Haploinsufficient Mice (In Utero and Postnatal Gavage Study): NTP GMM 14 [Internet].
Leakey JEA, Allaben WT, Dunnick JK, et al.
Research Triangle Park (NC): National Toxicology Program; 2013 Oct.
Copyright Notice

This is a work of the US government and distributed under the terms of the Public Domain

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.